Skip to Main Content

Karuna Therapeutics, a Boston-based biotech startup, said Monday it has raised $68 million in venture capital to advance clinical development of a radically different drug for schizophrenia.

The sum is on top of $42 million that Karuna, a privately held 10-year-old firm, raised last year for development of the experimental medicine, which company officials hope might cause fewer side effects than the schizophrenia drugs on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!